These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 16526983)

  • 1. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis.
    Klotz LH; Nam RK
    Can J Urol; 2006 Feb; 13 Suppl 1():48-55. PubMed ID: 16526983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer.
    Klotz L
    Nat Clin Pract Urol; 2005 Mar; 2(3):136-42; quiz 1 p following 149. PubMed ID: 16474710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease.
    Klotz LH
    Can J Urol; 2005 Feb; 12 Suppl 1():53-7; discussion 101-2. PubMed ID: 15780167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
    Klotz L
    Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.
    Klotz L
    Eur Urol; 2005 Jan; 47(1):16-21. PubMed ID: 15582244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active surveillance versus radical treatment for favorable-risk localized prostate cancer.
    Klotz L
    Curr Treat Options Oncol; 2006 Sep; 7(5):355-62. PubMed ID: 16904052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
    Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
    J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
    Krakowsky Y; Loblaw A; Klotz L
    J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active surveillance for prostate cancer: for whom?
    Klotz L
    J Clin Oncol; 2005 Nov; 23(32):8165-9. PubMed ID: 16278468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression.
    Dall'Era MA; Konety BR
    Nat Clin Pract Urol; 2008 May; 5(5):277-83. PubMed ID: 18285752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expectant management with selective delayed intervention for favorable-risk prostate cancer.
    Klotz LH; Choo R; Morton G; Danjoux C
    Can J Urol; 2002 Jun; 9 Suppl 1():2-7. PubMed ID: 12121587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].
    Leibovici D; Lindner A; Stay K; Zisman A
    Harefuah; 2006 Oct; 145(10):763-7, 781, 780. PubMed ID: 17111715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention.
    Klotz L
    Nat Clin Pract Urol; 2008 Jan; 5(1):2-3. PubMed ID: 18043601
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
    Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
    Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
    Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
    Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active surveillance for favorable risk prostate cancer: rationale, risks, and results.
    Klotz L
    Urol Oncol; 2007; 25(6):505-9. PubMed ID: 18047961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
    Johansson E; Bill-Axelson A; Holmberg L; Onelöv E; Johansson JE; Steineck G;
    Eur Urol; 2009 Feb; 55(2):422-30. PubMed ID: 18783877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
    Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active surveillance for good risk prostate cancer: rationale, method, and results.
    Klotz LH
    Can J Urol; 2005 Jun; 12 Suppl 2():21-4. PubMed ID: 16018828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.